Jason Beaubien
Jason Beaubien is NPR's Global Health and Development Correspondent on the Science Desk.
In this role, he reports on a range of issues across the world. He's covered the plight of Rohingya refugees in Bangladesh, mass cataract surgeries in Ethiopia, abortion in El Salvador, poisonous gold mines in Nigeria, drug-resistant malaria in Myanmar and tuberculosis in Tajikistan. He was part of a team of reporters at NPR that won a Peabody Award in 2015 for their extensive coverage of the West Africa Ebola outbreak. His current beat also examines development issues including why Niger has the highest birth rate in the world, can private schools serve some of the poorest kids on the planet and the links between obesity and economic growth.
Prior to becoming the Global Health and Development Correspondent in 2012, Beaubien spent four years based in Mexico City covering Mexico, Central America and the Caribbean. In that role, Beaubien filed stories on politics in Cuba, the 2010 Haitian earthquake, the FMLN victory in El Salvador, the world's richest man and Mexico's brutal drug war.
For his first multi-part series as the Mexico City correspondent, Beaubien drove the length of the U.S./Mexico border making a point to touch his toes in both oceans. The stories chronicled the economic, social and political changes along the violent frontier.
In 2002, Beaubien joined NPR after volunteering to cover a coup attempt in the Ivory Coast. Over the next four years, Beaubien worked as a foreign correspondent in sub-Saharan Africa, visiting 27 countries on the continent. His reporting ranged from poverty on the world's poorest continent, the HIV in the epicenter of the epidemic, and the all-night a cappella contests in South Africa, to Afro-pop stars in Nigeria and a trial of white mercenaries in Equatorial Guinea.
During this time, he covered the famines and wars of Africa, as well as inspiring preachers and Nobel laureates. Beaubien was one of the first journalists to report on the huge exodus of people out of Sudan's Darfur region into Chad, as villagers fled some of the initial attacks by the Janjawid. He reported extensively on the steady deterioration of Zimbabwe and still has a collection of worthless Zimbabwean currency.
In 2006, Beaubien was awarded a Knight-Wallace fellowship at the University of Michigan to study the relationship between the developed and the developing world.
Beaubien grew up in Maine, started his radio career as an intern at NPR Member Station KQED in San Francisco and worked at WBUR in Boston before joining NPR.
-
As the omicron variant of COVID-19 has spread rapidly around the world, some countries have re-imposed lockdowns.
-
Namibia's president says disparate global rates of vaccination represent "COVID apartheid." When you compare percent of people vaccinated in the most populous countries, you can understand his ire.
-
A rare blood clotting condition has occurred in some people after receiving the AstraZeneca COVID-19 vaccine. If the new research is correct, it could mean that blood clots could be easily treated.
-
Why are numbers so high in the region? Public health officials point to a number of underlying problems that let the coronavirus run amok.
-
Back-to-back hurricanes have taken an unprecedented toll on the Central American nation and its neighbors.
-
The No. 1 and 2 causes of death remain the same, but there have been a number of notable changes. And now there's a new disease to assess on the global landscape: COVID-19.
-
A new report describes a region where hunger and malnutrition are sharply increasing — and only likely to get worse as COVID-19 pushes more people into poverty.
-
The medicine is one of the few to win regulatory approval as a treatment for the disease, but has fallen out of favor with the health authority.
-
The drugs only need to be taken a few times a year — and may soon be available in many parts of the world. Patients say they are more convenient and less stigmatizing.
-
A single injection of a drug called cabotegravir given every two months has been shown to be more effective than a daily oral dose of Truvada.